Avantor (AVTR) Stock Overview
Engages in the provision of mission-critical products and services to customers in the biopharma, healthcare, education and government, advanced technologies, and applied materials industries in the Americas, Europe, Asia, the Middle East, and Africa. More details
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 3/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
AVTR Community Fair Values
Create NarrativeSee what 16 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Avantor, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$13.78 |
| 52 Week High | US$15.93 |
| 52 Week Low | US$7.27 |
| Beta | 0.94 |
| 1 Month Change | 37.66% |
| 3 Month Change | 73.12% |
| 1 Year Change | 21.30% |
| 3 Year Change | -33.43% |
| 5 Year Change | -63.76% |
| Change since IPO | -4.97% |
Recent News & Updates
Narrative Update • Jul 30
AVTR: Turnaround Execution And Sector Recovery Will Support Future Repricing
Analysts have raised Avantor's fair value estimate from $15.99 to $17.94, reflecting higher price targets across the Street following Q2 results and a management turnaround that is starting to appear in reported margins and growth assumptions. Analyst Commentary Recent Street commentary around Avantor has shifted toward a more constructive tone, with several firms resetting price targets higher following the latest Q2 earnings and early signs of progress under the new leadership team.
Narrative Update • Jul 14
AVTR: Sector Tailwinds And Execution Risks Will Likely Shape Next Phase
Avantor's updated analyst price target moves from $9.92 to $10.31, with analysts citing refreshed sector views, recent target hikes into the $10.50 to $11 range, and a higher assumed future P/E multiple as key supports for the revised valuation framework. Analyst Commentary Recent research on Avantor reflects a split view, with some analysts pointing to improving sector conditions and revised price targets, while others focus on ongoing growth and margin challenges.Recent updates
Narrative Update • Jul 30
AVTR: Turnaround Execution And Sector Recovery Will Support Future Repricing
Analysts have raised Avantor's fair value estimate from $15.99 to $17.94, reflecting higher price targets across the Street following Q2 results and a management turnaround that is starting to appear in reported margins and growth assumptions. Analyst Commentary Recent Street commentary around Avantor has shifted toward a more constructive tone, with several firms resetting price targets higher following the latest Q2 earnings and early signs of progress under the new leadership team.Narrative Update • Jul 14
AVTR: Sector Tailwinds And Execution Risks Will Likely Shape Next Phase
Avantor's updated analyst price target moves from $9.92 to $10.31, with analysts citing refreshed sector views, recent target hikes into the $10.50 to $11 range, and a higher assumed future P/E multiple as key supports for the revised valuation framework. Analyst Commentary Recent research on Avantor reflects a split view, with some analysts pointing to improving sector conditions and revised price targets, while others focus on ongoing growth and margin challenges.Analysis Article • Jun 17
Avantor (AVTR) Stock Could Be 34% Below Fair Value After Wolfe Research Downgrade
Wolfe Research’s new Underperform rating on Avantor (AVTR) has put fresh attention on the stock, as the firm pointed to ongoing growth and margin pressures, as well as market share losses in its VWR distribution business. See our latest analysis for Avantor. Avantor’s recent 1 day share price return declined 1.44%, extending a 7 day share price return decline of 3.43%. However, the 30 day share price return rose 25.59%, while the 1 year total shareholder return declined 27.22%. This indicates...
Narrative Update • Jun 15
AVTR: Compressed Margins And Shrinking Real Revenue Will Weigh On Future Returns
Analysts have trimmed the fair value estimate for Avantor to $7.00, reflecting a series of lower price targets and continued concerns about shrinking real revenue, margin compression, and execution risk, even though some expectations remain for improved growth and profitability over time. Analyst Commentary Recent Street research on Avantor has leaned cautious, with several bearish analysts cutting price targets and highlighting ongoing operational and profitability challenges.Narrative Update • Jun 01
AVTR: Reset Expectations And Quality Expansion Will Support Turnaround Execution And Repricing
Analysts have trimmed Avantor's fair value estimate by about $0.48 to $15.99, as recent price target cuts and concerns about execution, market share trends, and confidence in the turnaround story temper prior expectations. Analyst Commentary Street research on Avantor has centered on whether the current share price already reflects execution risk and the uncertainties around the turnaround plan.Narrative Update • May 01
AVTR: Reset Expectations And Execution Progress May Support Future Upside
Avantor's updated analyst price target moves lower by several dollars to reflect a reset in fair value to $9.92, as analysts reference reduced price targets across the Street and ongoing questions around market share trends and management execution. Analyst Commentary Recent Street research around Avantor clusters around lower price targets and a downgrade in rating, with most comments focused on valuation reset, market share questions, and confidence in management execution.Seeking Alpha • Apr 30
Avantor Q1 2026 Earnings Review: Stabilization Emerging, But Recovery Not Yet Visible
Summary Avantor, Inc. reported a slight beat on 1Q26 EPS and revenue, but underlying organic growth and margins remain under pressure. Negative organic growth, margin compression, and subdued cash flow signal only early stabilization, not a confirmed recovery, especially in the VWR segment. Management reaffirmed 2026 guidance and expects sequential improvement, but the recovery is execution-dependent and gradual, with margins likely to remain below historical peaks. Valuation screens as discounted, but low multiples reflect market skepticism about AVTR’s growth durability and margin structure; a hold rating is maintained pending clearer evidence of turnaround. Read the full article on Seeking AlphaNarrative Update • Apr 16
AVTR: Expanded Quality Control Capabilities Will Support Execution Turnaround And Future Share Repricing
Analysts have trimmed their average price targets on Avantor, and the updated fair value estimate now stands at about $16.47. This reflects a softer sentiment around the stock as research notes point to share losses, reduced investment, and questions about management's ability to stabilize the business.Narrative Update • Apr 02
AVTR: Reset Expectations And Share Repurchases May Support Future Upside
The analyst price target for Avantor has shifted lower to reflect a series of Street target cuts, including a move to $8.50. This change stems from concerns about share losses, constrained investment, and uncertainty over whether management can stabilize the business.Narrative Update • Mar 19
AVTR: Execution Turnaround In Core Franchise Will Drive Future Share Repricing
Analysts have lowered their price targets on Avantor, with the updated fair value estimate moving from about $17.68 to $16.13 as they factor in concerns about share losses, underinvestment, and uncertainty around management's ability to stabilize the business, along with a higher assumed discount rate and P/E multiple. Analyst Commentary Recent Street research has tilted cautious on Avantor, highlighted by a downgrade to Underweight with a US$8.50 price target and several cuts to prior price targets.Narrative Update • Mar 05
AVTR: Reset Expectations And Buybacks Will Support Future Upside Potential
Analysts have cut their average price target on Avantor by a few dollars to reflect lower fair value estimates, softer assumed revenue growth and profit margins, and a higher future P/E multiple in light of recent broad target reductions from firms across the Street. Several have moved targets in a $2 to $4 range, and one reset its view from $14 to $12.Analysis Article • Feb 13
The Market Doesn't Like What It Sees From Avantor, Inc.'s (NYSE:AVTR) Revenues Yet As Shares Tumble 27%
Avantor, Inc. ( NYSE:AVTR ) shares have had a horrible month, losing 27% after a relatively good period beforehand...Narrative Update • Feb 04
AVTR: Service Expansion And Execution Will Drive Upside From Reset Expectations
Narrative Update: Avantor Analyst Price Target Shift Analysts recently trimmed their price target on Avantor to $12 from $14. This reflects updated views on the life science tools sector and a Q4 outlook where many companies have already set softer expectations for 2026.Narrative Update • Jan 21
AVTR: Share Repurchases And Execution Risks Will Shape Turnaround Visibility
Analysts have trimmed their price target on Avantor by about $0.60, reflecting more cautious assumptions on revenue growth and future P/E. This is partly offset by slightly higher profit margin expectations and a marginally lower discount rate.Narrative Update • Jan 07
AVTR: Execution Turnaround And Review Process Will Unlock Share Repricing Potential
Avantor's analyst price targets and fair value estimates have inched higher to around $17.68 per share. At the same time, lower assumed revenue growth, a higher discount rate, a reduced future P/E, and sharply higher profit margin expectations reflect analysts' mixed views following recent downgrades and concerns about execution and visibility.Narrative Update • Dec 14
AVTR: Share Repurchases Will Drive Upside As Turnaround Visibility Improves
Analysts have modestly lowered their price targets on Avantor by a few dollars per share, generally to the low to mid teens in dollar terms. They cite reduced guidance, weaker quarters and limited visibility around the company’s turnaround and strategic review.Narrative Update • Nov 28
AVTR: Share Repurchase Initiative And Execution Will Shape Recovery Prospects Ahead
Analysts have lowered their price target for Avantor from $14 to $12 per share, citing a weak quarter, reduced guidance, and ongoing execution risks as primary concerns behind the updated outlook. Analyst Commentary Bullish Takeaways Bullish analysts have raised price targets ahead of quarterly results, reflecting improved confidence in Avantor’s long-term positioning despite current volatility.Narrative Update • Nov 14
AVTR: Share Repurchase And Execution Will Define Turnaround Prospects In 2025
Avantor’s analyst price target has decreased from $13.80 to $13.64. Analysts cite reduced company guidance, execution risks, and ongoing uncertainty surrounding its earnings outlook as key factors driving the revision.Analysis Article • Nov 01
Avantor, Inc. Reported A Surprise Loss, And Analysts Have Updated Their Forecasts
There's been a major selloff in Avantor, Inc. ( NYSE:AVTR ) shares in the week since it released its third-quarter...Narrative Update • Oct 31
AVTR: Activist Pressure And Business Overhaul Will Drive Share Recovery
Avantor’s analyst price target has been reduced from $14.40 to $13.80 per share, as analysts cite ongoing operational headwinds and limited near-term earnings visibility following recent downgrades and mixed guidance. Analyst Commentary Recent analyst notes on Avantor capture a divided outlook, reflecting both positive updates from some firms and notable caution from others as the company contends with ongoing operational challenges.Analysis Article • Oct 28
There's No Escaping Avantor, Inc.'s (NYSE:AVTR) Muted Earnings Despite A 28% Share Price Rise
Avantor, Inc. ( NYSE:AVTR ) shares have had a really impressive month, gaining 28% after a shaky period beforehand...Narrative Update • Oct 16
Pharma Contracts And R&D Will Drive Growth Amid Price Pressures
Analysts have modestly increased their price target for Avantor, raising it by $0.28 to $14.40. They cite revised expectations for end market recovery and alignment with company outlooks.Analysis Article • Sep 12
We Think Avantor (NYSE:AVTR) Is Taking Some Risk With Its Debt
Warren Buffett famously said, 'Volatility is far from synonymous with risk.' When we think about how risky a company...Analysis Article • Aug 12
Concerns Surrounding Avantor's (NYSE:AVTR) Performance
NYSE:AVTR 1 Year Share Price vs Fair Value Explore Avantor's Fair Values from the Community and select yours Avantor...Seeking Alpha • Apr 26
Avantor: A Healthier Diagnosis As Expectations Cool
Summary Avantor's shares have nearly halved since October, driven by lackluster organic growth, elevated debt, and a mixed financial track record. The company operates in two segments, generating nearly $7 billion in sales, with significant exposure to laboratory solutions and bioscience production. Despite a reduction in net debt and lower earnings multiples, the business faces ongoing challenges, including flat organic growth and a high leverage ratio. The risk-reward profile has improved due to lower expectations, but the outlook remains cautious amidst continued sales declines and pending leadership changes. Read the full article on Seeking AlphaSeeking Alpha • Mar 07
Avantor: Mundane Business, Solid Cash Flow, Potential New Risks
Summary Avantor, Inc. has seen a significant decline in its stock price recently. The company did divest itself of one business this summer, paying down some debt with the proceeds. In addition, the company delivered an impressive amount of free cash flow in FY2024. Buy, Sell or Hold? An analysis around AVTR stock follows in the paragraphs below. Read the full article on Seeking AlphaSeeking Alpha • Dec 18
Avantor: Durable FCF Generator Trading For Cheap
Summary Avantor's robust business model yields stable cash flows and generates sticky customers. Avantor’s leadership in the biopharma industry and shifting revenue mix can produce considerable margin expansion. Significant FCF generation can improve the company’s capital structure and return value to shareholders. Potential industry inflection point creates optimal entry point with multiple expansion. Read the full article on Seeking AlphaShareholder Returns
| AVTR | US Life Sciences | US Market | |
|---|---|---|---|
| 7D | 20.5% | 1.8% | 0.5% |
| 1Y | 21.3% | 20.0% | 16.5% |
Return vs Industry: AVTR exceeded the US Life Sciences industry which returned 20% over the past year.
Return vs Market: AVTR exceeded the US Market which returned 16.5% over the past year.
Price Volatility
| AVTR volatility | |
|---|---|
| AVTR Average Weekly Movement | 8.0% |
| Life Sciences Industry Average Movement | 8.5% |
| Market Average Movement | 7.2% |
| 10% most volatile stocks in US Market | 16.3% |
| 10% least volatile stocks in US Market | 3.2% |
Stable Share Price: AVTR has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: AVTR's weekly volatility (8%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1904 | 13,500 | Emmanuel Ligner | www.avantorsciences.com |
Avantor, Inc. engages in the provision of mission-critical products and services to customers in the biopharma, healthcare, education and government, advanced technologies, and applied materials industries in the Americas, Europe, Asia, the Middle East, and Africa. The company offers materials and consumables, such as purity chemicals and reagents, lab products and supplies, formulated silicone materials, customized excipients, customized single-use assemblies, process chromatography resins and columns, analytical sample prep kits, education and microbiology products, clinical trial kits, and fluid handling tips. It also provides equipment and instrumentation products, including filtration systems, virus inactivation systems, incubators, analytical instruments, evaporators, ultra-low-temperature freezers, biological safety cabinets, peristaltic pumps, and critical environment supplies.
Avantor, Inc. Fundamentals Summary
| AVTR fundamental statistics | |
|---|---|
| Market cap | US$9.37b |
| Earnings (TTM) | -US$578.00m |
| Revenue (TTM) | US$6.56b |
1.4x
P/S Ratio-16.1x
P/E RatioIs AVTR overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| AVTR income statement (TTM) | |
|---|---|
| Revenue | US$6.56b |
| Cost of Revenue | US$4.47b |
| Gross Profit | US$2.09b |
| Other Expenses | US$2.67b |
| Earnings | -US$578.00m |
Last Reported Earnings
Jun 30, 2026
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.85 |
| Gross Margin | 31.83% |
| Net Profit Margin | -8.81% |
| Debt/Equity Ratio | 65.2% |
How did AVTR perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/07/31 22:10 |
| End of Day Share Price | 2026/07/31 00:00 |
| Earnings | 2026/06/30 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Avantor, Inc. is covered by 29 analysts. 15 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Robert Bamberger | Baird |
| Catherine Ramsey Schulte | Baird |
| Luke Sergott | Barclays |